Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2017’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)

The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects

The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

Azevan Pharmaceuticals Inc

Bionomics Ltd

Catalyst Pharmaceuticals Inc

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Eli Lilly and Company

Embera NeuroTherapeutics Inc

Intra-Cellular Therapies Inc

INVENT Pharmaceuticals Inc

Marinus Pharmaceuticals Inc

Neuralstem Inc

NeuroNascent Inc

Omeros Corp

Otsuka Holdings Co Ltd

Pragma Therapeutics SAS

Synchroneuron Inc

Tonix Pharmaceuticals Holding Corp

TRImaran Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post-Traumatic Stress Disorder (PTSD) - Overview

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

Azevan Pharmaceuticals Inc

Bionomics Ltd

Catalyst Pharmaceuticals Inc

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Eli Lilly and Company

Embera NeuroTherapeutics Inc

Intra-Cellular Therapies Inc

INVENT Pharmaceuticals Inc

Marinus Pharmaceuticals Inc

Neuralstem Inc

NeuroNascent Inc

Omeros Corp

Otsuka Holdings Co Ltd

Pragma Therapeutics SAS

Synchroneuron Inc

Tonix Pharmaceuticals Holding Corp

TRImaran Pharma Inc

Post-Traumatic Stress Disorder (PTSD) - Drug Profiles

(metyrapone + oxazepam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acamprosate calcium SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexpiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganaxolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-87201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDAC-0001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumateperone tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midomafetamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

modafinil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGT-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rycal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Target NPSR for Anxiety Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tianeptine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZL-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

Featured News & Press Releases

Feb 09, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference

Jan 24, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13

Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference

Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-102 at 9th Annual Biotech Showcase Conference

Jan 05, 2017: Marinus Provides Business Outlook for 2017

Jan 03, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference

Dec 19, 2016: Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

Dec 08, 2016: Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder

Dec 02, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Nov 10, 2016: Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD

Nov 07, 2016: Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting

Nov 02, 2016: Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference

Nov 01, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress

Oct 27, 2016: Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Addex Therapeutics Ltd, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Amorsa Therapeutics Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Azevan Pharmaceuticals Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Bionomics Ltd, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Catalyst Pharmaceuticals Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Cerecor Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Chronos Therapeutics Ltd, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Corcept Therapeutics Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Eli Lilly and Company, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Embera NeuroTherapeutics Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Intra-Cellular Therapies Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Marinus Pharmaceuticals Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Neuralstem Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by NeuroNascent Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Omeros Corp, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Pragma Therapeutics SAS, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Synchroneuron Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Pipeline by TRImaran Pharma Inc, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Dormant Projects, H1 2017

Post-Traumatic Stress Disorder (PTSD) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Post-Traumatic Stress Disorder (PTSD) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports